Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India

MT Newswires Live11-28

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has launched its immuno-oncology drug Toripalimab in India and will market it under the brand name Zytorvi, according to a Thursday filing to the stock exchanges.

In 2023, Dr. Reddy's entered into a licensing and commercialization deal with Junshi Biosciences (SHA:688180, HKG:1877) for Toripalimab, which is approved by various regulatory authorities globally for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.

Under the pact, Dr. Reddy's obtained exclusive rights to develop and commercialize Toripalimab in 21 markets, including India, South Africa, Brazil, and various countries in Latin America.

Shares of the company were down nearly 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486981364?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-28 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486981364","market":"sg","top_or_hot":-1,"title":"Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India","media":"MT Newswires Live","content":"<html><body><p> Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has launched its immuno-oncology drug Toripalimab in India and will market it under the brand name Zytorvi, according to a Thursday filing to the stock exchanges.</p><p>In 2023, Dr. Reddy's entered into a licensing and commercialization deal with Junshi Biosciences (SHA:688180, HKG:1877) for Toripalimab, which is approved by various regulatory authorities globally for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.</p><p>Under the pact, Dr. Reddy's obtained exclusive rights to develop and commercialize Toripalimab in 21 markets, including India, South Africa, Brazil, and various countries in Latin America.</p><p>Shares of the company were down nearly 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr. Reddy's Launches Toripalimab Immuno-oncology Drug in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 14:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has launched its immuno-oncology drug Toripalimab in India and will market it under the brand name Zytorvi, according to a Thursday filing to the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486981364","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486981364","pubTimestamp":1732774709,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dr. Reddy's Laboratories  has launched its immuno-oncology drug Toripalimab in India and will market it under the brand name Zytorvi, according to a Thursday filing to the stock exchanges.In 2023, Dr. Reddy's entered into a licensing and commercialization deal with Junshi Biosciences  for Toripalimab, which is approved by various regulatory authorities globally for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.Under the pact, Dr. Reddy's obtained exclusive rights to develop and commercialize Toripalimab in 21 markets, including India, South Africa, Brazil, and various countries in Latin America.Shares of the company were down nearly 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK1583":"高瓴概念","BK0239":"医药制造","BK1515":"抗疫概念","01877":"君实生物","BK1161":"生物科技"},"translate_title":"Dr.Reddy's在印度推出特瑞普利单抗免疫肿瘤药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"01877":0.9},"content_text":"Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has launched its immuno-oncology drug Toripalimab in India and will market it under the brand name Zytorvi, according to a Thursday filing to the stock exchanges.In 2023, Dr. Reddy's entered into a licensing and commercialization deal with Junshi Biosciences (SHA:688180, HKG:1877) for Toripalimab, which is approved by various regulatory authorities globally for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.Under the pact, Dr. Reddy's obtained exclusive rights to develop and commercialize Toripalimab in 21 markets, including India, South Africa, Brazil, and various countries in Latin America.Shares of the company were down nearly 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486981364"}